A Fatal Complication of Liver Transplant: Posttransplant Lymphoproliferative Disease.

---

Atıf İçin Kopyala

HIZARCIOĞLU GÜLŞEN H., GÜMÜŞ E., DEMİR H., Saltik-Temizel İ. N., VARAN A., DİNÇER H. A., ...Daha Fazla

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, cilt.20, sa.Suppl 3, ss.102-104, 2022 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 20 Sayı: Suppl 3
• Basım Tarihi: 2022
• Doi Numarası: 10.6002/ect.pediatricsymp2022.o33
• Dergi Adı: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
• Sayfa Sayıları: ss.102-104
• Anahtar Kelimeler: Cytomegalovirus, Epstein-Barr virus, Lymphoma, Tacrolimus
• Hacettepe Üniversitesi Adresli: Evet

Özet

© Başkent University 2022 Printed in Turkey. All Rights Reserved.Immunosuppressive therapy is a double-edged sword and causes a risk for some complications, such as opportunistic infections and posttransplant lymphoproliferative disease. The most likely risk factors for posttransplant lymphoproliferative disease are Epstein-Barr virus serology mismatch, prolonged and high viral load for Epstein-Barr virus, higher doses of immunosuppressive therapy, and cytomegalovirus infection. Transplant recipients who are seropositive for Epstein-Barr virus show a lower risk for posttransplant lymphoproliferative disease than seronegative recipients. Here, we present a 3.5-year-old boy who was seropositive for Epstein-Barr virus and developed posttransplant lymphoproliferative disease 18 months after liver transplant with a previous history of cytomegalovirus-related pneumatosis intestinalis.